Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (431-440 of 643) with videos related to

Pageof 65
Sort By:
Cancer|October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancersFilip Janku, Divya Sakamuri, Shumei Kato, et al.
JCO Precision Oncology|February 9, 2022
Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical PhenotypeApurva Jain, Mitesh J Borad, Robin Kate Kelley, et al.
Cancer Research Communications|August 5, 2025
Phase 2 Study of Zilovertamab Vedotin in Participants With Metastatic Solid TumorsFunda Meric-Bernstam, Martin Gutierrez, Enrique Sanz-Garcia, et al.
Cancer Research Communications|December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid MalignanciesVivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
Experimental Hematology & Oncology|December 30, 2021
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumorsKyaw Z Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Scientific Reports|May 24, 2022
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiencesShuyang Yao, Funda Meric-Bernstam, David Hong, et al.
JCO Precision Oncology|October 16, 2018
Clinical Use of Precision Oncology Decision SupportAmber Johnson, Yekaterina B Khotskaya, Lauren Brusco, et al.
Clinical Breast Cancer|July 29, 2014
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unitDebora de Melo Gagliato, Denis L Fontes Jardim, Gerald Falchook, et al.
Annals of Surgical Oncology|August 27, 2013
Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted?Elizabeth Fitzsullivan, Sara A Lari, Benjamin Smith, et al.
Oncotarget|May 10, 2014
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsJennifer J Wheler, Barbara A Parker, Jack J Lee, et al.
Pageof 65

Showing results (431-440 of 643) with videos related to

Sort By:
Pageof 65
Cancer|October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancersFilip Janku, Divya Sakamuri, Shumei Kato, et al.
JCO Precision Oncology|February 9, 2022
Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical PhenotypeApurva Jain, Mitesh J Borad, Robin Kate Kelley, et al.
Cancer Research Communications|August 5, 2025
Phase 2 Study of Zilovertamab Vedotin in Participants With Metastatic Solid TumorsFunda Meric-Bernstam, Martin Gutierrez, Enrique Sanz-Garcia, et al.
Cancer Research Communications|December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid MalignanciesVivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
Experimental Hematology & Oncology|December 30, 2021
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumorsKyaw Z Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Scientific Reports|May 24, 2022
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiencesShuyang Yao, Funda Meric-Bernstam, David Hong, et al.
JCO Precision Oncology|October 16, 2018
Clinical Use of Precision Oncology Decision SupportAmber Johnson, Yekaterina B Khotskaya, Lauren Brusco, et al.
Clinical Breast Cancer|July 29, 2014
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unitDebora de Melo Gagliato, Denis L Fontes Jardim, Gerald Falchook, et al.
Annals of Surgical Oncology|August 27, 2013
Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted?Elizabeth Fitzsullivan, Sara A Lari, Benjamin Smith, et al.
Oncotarget|May 10, 2014
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsJennifer J Wheler, Barbara A Parker, Jack J Lee, et al.
Pageof 65